ArticleAdvances in experimental medicine and biology2021
Clinically Compatible Fluorescence Microscopy Based on Moxifloxacin Antibiotic.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-resolution fluorescence tissue imaging with the application of moxifloxacin as a cell-labelling agent is described. Moxifloxacin is an antibiotic used in the clinic to both treat and prevent bacterial infections, and it has both good pharmacokinetic properties for tissue penetration and intrinsic fluorescence under ultraviolet (UV) excitation. Alternative usage of moxifloxacin as the cell-labelling agent was discovered and its imaging applications have been explored. With moxifloxacin administration, fluorescence microscopy could visualize cells within tissues either in enhanced contrasts or at high imaging speeds. Both linear and nonlinear fluorescence microscopies could be used for moxifloxacin-based tissue imaging. High-contrast cellular imaging was demonstrated in various tissues including the cornea, skin, small and large intestines, and brain. Moxifloxacin-based fluorescence microscopy can be clinically compatible by using the FDA-approved moxifloxacin and it could be used for both diagnosis and surgery guidance. Moxifloxacin-based fluorescence microscopy has been tested in several preclinical studies, including the detection of infecting pathogens in fungal keratitis, and the delineation of tumor margin in brain tumor and skin cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.